HIV Mutation Detail Information

> Q148H Search Result

Mutation Information

Mutation Site	Q148H
Mutation Type	Amino acid level
Gene/Protein/Region Type	IN
Combined Mutation	in.Q148H+in.G140S
Relevant Drug	raltegravir (RAL);elvitegravir (EVG)

Literature Information

PubMed PMID	32389483
Published Year	2020
Journal	Bioorganic & medicinal chemistry
Title	Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors.
Author	Patel M,Naidu BN,Dicker I,Higley H,Lin Z,Terry B,Protack T,Krystal M,Jenkins S,Parker D,Panja C,Rampulla R,Mathur A,Meanwell NA,Walker MA
Evidence	The [3.2.2]-bridged tricyclic system was identified as an advantageous chemotype, with representatives exhibiting excellent antiviral activity against both wild-type viruses and the G140S/Q148H resistant virus that arises in response to therapy with raltegravir and elvitegravir.

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation